2Q 2025 financial results July 31, 2025 Prepared remarks These slides should be reviewed with the accompanying prepared remarks posted on our website. Forward-looking statements The information in this release and other statements by the company may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to, among other items: projections and estimates of earnings, revenues, volumes, pricing, margins, cost reductions, expenses, taxes, liquidity, cap ...

Financial Performance - Organic sales growth for Q2 2025 was 3.9% [43], driven by strong volume growth in North America and International Personal Care [16] - Adjusted operating profit growth for Q2 2025 decreased by 2.2% [43] - Adjusted EPS growth attributable to Kimberly-Clark for Q2 2025 decreased by 2.0% [43] - Adjusted free cash flow year-to-date is $829 million [43] - The company is targeting 5-6% gross productivity savings in 2025 [34] Business Strategy and Initiatives - The company announced a $2 billion investment in North America to support growth and unlock efficiencies [10, 16] - A joint venture with Suzano was announced to create a preeminent international tissue and professional products company [12, 16, 38] - The company streamlined product platforms from 30 to 11 to drive simplicity and improve quality [36, 37] Segment Performance - North America experienced organic growth of 4.5% in Q2 2025 [45], driven by 5% volume growth [47] - International Personal Care saw organic growth of 6.0% in Q2 2025 [48], with focus markets growing volume by 8% [50] 2025 Outlook - The company anticipates low-to-mid single-digit organic sales growth ahead of market growth in constant currency [51] - Adjusted free cash flow for 2025 is expected to be approximately $2 billion, including $1.0-$1.2 billion in capital expenditures [51]

Q2 2025 Earnings Earnings Presentation August 1, 2025 Disclaimer Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-looking s ...

Financial Performance - Total revenue for Q2 2025 was $142 million, a decrease of 41% compared to $241 million in Q2 2024[12] - Net product sales decreased by 38%, from $184 million in Q2 2024 to $114 million in Q2 2025[12] - Net loss was $825 million in Q2 2025, a 35% improvement compared to a net loss of $1279 million in Q2 2024[12] - Operating expenses decreased by 35%, a reduction of $555 million, from $1604 million in Q2 2024 to $1049 million in Q2 2025[8, 12] - Cash, cash equivalents, and investments decreased by 11%, from $84 billion as of March 31, 2025, to $75 billion as of June 30, 2025[8, 14] Pipeline and Approvals - The company received three new U S FDA approvals, expanding the commercial portfolio[9] - Positive Phase 3 data for mRNA-1010, the flu vaccine, showed superior relative vaccine efficacy compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older[9, 35] Financial Outlook and Cost Reduction - The company updated its 2025 GAAP financial framework, lowering the high end of the total revenue range from $25 billion to $15 - $22 billion, primarily due to the timing of UK COVID shipments moving from 2H25 to 1Q26[15] - The company is reducing 2025 GAAP operating expenses by approximately $04 billion and progressing toward intermediate-term cost reduction goals[16] - The company continues to target cash breakeven in 2028[55]

Company Overview - Interface reported net sales of $1.3 billion in FY2024[9] - The company has a global presence with 6 manufacturing locations on 4 continents[9] - Interface is recognized as a leader in sustainability with over 50 years of innovation[11] Financial Performance (Q2 2025) - Net sales increased by 8.3% year-over-year to $375.5 million[63, 64, 66] - Currency neutral net sales increased by 7.1% year-over-year to $371.1 million[63, 80] - Gross profit increased by 20.7% to $148.0 million, representing 39.4% of net sales[64] - Operating income increased by 36.4% to $52.0 million, representing 13.9% of net sales[64] - Adjusted operating income increased by 41.2% to $55.9 million, representing 14.9% of net sales[63, 66] - Adjusted EBITDA was $64.8 million, representing 17.3% of net sales[66] - Adjusted earnings per share was $0.60[63, 66] Sustainability Metrics (2024) - Scope 1 emissions reduced by 30%[49] - Scope 2 emissions reduced by 28%[49] - Scope 3 emissions (Purchased Goods & Services) reduced by 42%[49] - 80% of total energy sourced at manufacturing sites is renewable[52]

Q2 2025 Earnings Release Supplement T. Rowe Price Group, Inc. August 1, 2025 A copy of this presentation, which includes additional information, is available at investors.troweprice.com. Data as of June 30, 2025, unless otherwise noted. All figures are USD, unless otherwise noted. Forward-Looking Statement This presentation, and other statements that T. Rowe Price may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to T. Rowe Pric ...

01 AUGUST 2025 Q2 2025 EARNINGS RESULTS MINING TO EMPOWER PEOPLE AND ADVANCE SOCIETIES NYSE │ JSE │ GSE Geita, Tanzania INVESTOR NOTE │ DISCLAIMER The information included in this presentation has not been reviewed or reported on by AngloGold Ashanti's external auditors. Non-GAAP financial measures This communication may contain certain "Non-GAAP" financial measures, including, for example, "total cash costs", "total cash costs per ounce", "all-in sustaining costs", "all-in sustaining costs per ounce", "ave ...

Financial Performance - Net income reached $299 million[20] - Diluted earnings per share (EPS) amounted to $197[20] - The net interest margin stood at 417%[20] - Return on average assets was 151%[10] - Return on average equity was 1550%[10] Balance Sheet & Capitalization - Total assets reached $81 billion[10] - Total gross loans amounted to $56 billion[10] - Total deposits reached $64 billion[10] - The loan-to-deposit ratio was 875%[20,37] - Uninsured deposits represented 307% of total deposits, totaling $196 billion[20,37] - Total risk-based capital ratio was 1526%[20]

Business Overview and Strategy - The Platform Group (TPG) operates as a software-enabled group of e-commerce platforms connecting partners and customers in niche segments[14] - TPG aims to become Europe's leading profitable platform group through organic growth, acquisitions (3-8 companies per year), and software platform improvements[43, 44, 45] - TPG's strategy involves a balanced organic and inorganic growth approach (50/50), expanding to 30 industries by 2025, and extending partnerships and service offerings[45] Recent Developments - TPG acquired We Connect Work, a B2B construction platform, with closing expected in August 2025[16, 20] - Expanded the French luxury platform Joli Closet (B2C), with closing in July 2025, integrating it with Fashionette, Winkelstraat, and Brandfield[22, 25] - Entered the Optics & Hearing segment (B2C) with an online platform and 30 local stores, projecting €55-60 million in revenue for FY 2026e with a 25% EBITDA margin[27, 31] Financial Performance and Outlook - Q1 2025 GMV reached €356.3 million, and net revenue was €160.8 million[55] - Q1 2025 Adjusted EBITDA was €15.9 million (9.9% margin), and net profit was €18.2 million[55, 57] - The company increased its FY2025 revenue guidance to €715-735 million, with adjusted EBITDA of €54-58 million and GMV of €1.3 billion[72] Key Performance Indicators - The number of partners increased to 15,348 as of March 31, 2025[63, 66] - Active customers (LTM) grew to 5.7 million in Q1 2025[63, 66] - Average order value increased to €125 in Q1 2025, up from €115 in 2024[63, 66] Debt and Capital Structure - As of December 31, 2024, TPG had cash and cash equivalents of €22.1 million, long-term debt of €33.1 million, short-term debt of €26.1 million, and a bond of €50.0 million[105] - Net debt was €87.1 million, with a leverage ratio of 2.6x EBITDA[105] - The company targets a leverage ratio of 1.5-2.3x LTM EBITDA for 2025-2026[106]

Financial Performance - Melrose Industries PLC reported a 6% increase in revenue to £1.72 billion in H1 2025[9] - The company achieved a 29% increase in operating profit to £310 million[9] - Free cash flow improved by £91 million year-over-year, although it remained an outflow of £54 million[9, 14] - Diluted earnings per share increased by 30% to 15.1p[14] Divisional Results - The Engines division saw an 11% increase in revenue, reaching £781 million, and a 26% increase in operating profit[16, 21] - The Structures division experienced a 3% increase in revenue to £939 million and a 32% increase in operating profit[16, 29] - Engines operating margin improved by 4.0 percentage points to 33.4%, while Structures operating margin increased by 2.0 percentage points to 6.7%[16] Strategic Initiatives - The company is in the final stages of footprint rationalization, reducing sites from 52 to 32[11] - 85% of the defence portfolio is now sustainably priced, ahead of schedule[11] Future Outlook - The company maintains its full-year guidance for 2025, expecting to deliver £100 million+ in free cash flow[8, 43] - Revenue target for 2029 is ~£5 billion, with operating profit of £1.2 billion+ and a margin up to 24%+[79]